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Abstract
With the emergence of the 2009 A(H1N1) pandemic influenza virus and the
rapid spread of drug resistance in recent years, the need to develop new anti-
influenza drugs that can reduce the emergence of new resistant viruses is both
urgent and important. This thesis explores the use of polymer-attached inhibitors as
a new approach in the development of anti-influenza drugs, with particular focus on
polymer-attached zanamivir (ZA). We have previously shown that covalently
conjugating multiple copies of ZA via a flexible linker to poly-L-glutamine greatly
enhances antiviral potency.
In the first study, we have elucidated the mechanism of this phenomenon.
Like ZA itself, the polymer-attached inhibitor binds specifically to viral
neuraminidase and inhibits both its enzymatic activity and the release of newly
synthesized virions from infected cells. In contrast to monomeric ZA, however, the
polymer-attached drug also synergistically inhibits virus-endosome fusion, thus
contributing to the dramatically increased antiviral potency.
Next, we went on to investigate polymer-attached ZA's effect on the
emergence of drug resistance. We found that viruses adapted rapidly to growing in
high concentrations of monomeric ZA, whereas viral growth remained inhibited by
low concentrations of polymer-attached ZA even after 23 passages in cell culture.
Sequencing analysis established the emergence of an amino acid substitution known
to confer ZA resistance (E119G in neuraminidase) after 8 passages of monomeric ZA
selection. In contrast, virus grown in polymer-attached ZA remained free of
substitutions in E119, and other known resistance-associated residues. We instead
found novel substitutions in hemagglutinin (R220G, D241G) and neuraminidase
(G111D), which emerged during passages 14-17. Importantly, although the drug-
selected variants were resistant to monomeric ZA, the viruses remained susceptible
to low pM concentrations of polymer-attached ZA itself.
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Taken together, these data demonstrate that attaching the drug to a
polymeric chain (i) confers a new mechanism of antiviral action; (ii) significantly
delays the emergence of drug resistance; and (iii) enhances potency against the
selected ZA-resistant variants. The studies presented in this thesis provide further
impetus for the use of polymer-attached inhibitors as influenza therapy, and as tools
for better understanding of influenza biology.
Thesis co-advisor: Alexander M. Klibanov, Ph.D.
Title: Firmenich Chair Professor of Chemistry & Bioengineering, M.I.T.
Thesis co-advisor: Jianzhu Chen, Ph.D.
Title: Ivan R. Cottrell Professor of Immunology and Professor of Biology, M.I.T.
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Chapter 1: Introduction
Chapter 1
INTRODUCTION
1.1 Influenza A virus
Influenza A virus is a negative-sense, single-stranded RNA virus from the
Orthomyxoviridae family. It causes highly contagious infections of the human respiratory
tract (1). Millions of people are struck by influenza infection each year, resulting in more
than 500,000 deaths worldwide. In the US alone, annual influenza epidemics affect 6-15%
of the population, causing severe suffering and economic loss (2, 3). During a pandemic, the
effects are far more deadly. An estimated 50 million lives were lost in the 1918 "Spanish
flu" pandemic, widely regarded as the most devastating pandemic in recorded world
history (4).
Influenza virus is an enveloped virus containing eight genome segments which
encodes for ten proteins (Figure 1) (1). The three largest RNA segments encode for the
proteins which make up the RNA-dependent RNA polymerase complex: PB1, PB2, and PA.
The next three segments encode for hemagglutinin (HA), nucleoprotein (NP) and
neuraminidase (NA). Other proteins encoded by the remaining segments are the M1 matrix
protein, M2 ion-channel protein and non-structural proteins NS1 and NS2. There are three
proteins on the viral surface: glycoproteins HA and NA, the two principal viral antigens (5),
and the M2 ion channel. The main functions of HA are binding to the host receptor sialic
acid and mediating viral and endosomal membrane fusion (6), whereas NA is known to
facilitate the release of newly synthesized viruses from infected cells by cleavage the sialic
11
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acid receptor (7, 8). These roles of HA and NA, and that of other viral proteins in the life
cycle of influenza virus are depicted in Figure 2.
The widespread 2009 A(H1N1) pandemic, constant antigenic drift of seasonal
influenza, and the rapid emergence of antiviral resistance in recent years highlight the
ability of this pathogen in adapting to the human population and in evading antiviral drugs
(9). The survival and persistence of influenza virus can be attributed to several of its
unique properties. First, the virus transmits easily from person to person by aerosol, and
spreads globally through travel and migratory birds. Second, the error-prone viral RNA
polymerase lacks proofreading ability, resulting in a high mutation rate of 1.5 x 10-s per
nucleotide per infection cycle (10). Given the size of the influenza genome of 15,000 bases,
this corresponds to an average of one mutation for every 10 viruses produced by an
infected cell. This error-prone replication, coupled with the selective pressure of the
immune system readily promotes the antigenic variation in the viral proteins HA and NA
amongst seasonal influenza strains (11). The high mutation rate is also the driving force
behind the appearance of drug resistant strains, either in naturally occurring variants, or
by drug selection pressure in treated patients (12-14). Third, the segmented nature of the
influenza genome allows for mixing or reassortment of the eight viral gene segments,
which can occur in cells infected with two different influenza viruses (15, 16). The resulting
hybrid may contain gene segments from influenza viruses of different species, and can be
especially virulent as the population lacks previous exposure to the newly introduced
protein subtypes. Termed antigenic shift, this mechanism underlies the emergence of all
three influenza pandemics since the 1918 Spanish flu (17).
12
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N S2
PB1, PB2, PA
(Transcriptase complex) NP (Nucleocapsid)
Figure 1. Schematic diagram of influenza A virus. Influenza A virus is an enveloped,
negative-sense, single-stranded RNA virus. Within the lipid bilayer enveloped, the virus has
eight gene segments, which encode for the ten proteins. The viral surface is decorated with
spike-like projections of the glycoproteins HA and NA, which are inserted in the lipid
bilayer.
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Figure 2. Stages of influenza virus replication. (i) Attachment: Influenza viruses attach
to host cells via multivalent interactions of HA with sialic acids on cell surface
glycoproteins to initiate infection and replication. (ii) Entry: The virus is then internalized
by endocytic compartments. (iii) Fusion and uncoating: The H+ ions enter the virus through
the M2 ion channel, and the low pH triggers a conformational change in HA. This activates
virus-endosome fusion, and releases the genomic contents into the cytosol. (iv)
Intracellular processes: The viral genome is transported into the nucleus, where viral RNA
synthesis is carried out by the RNA-dependent RNA polymerase complex, and the viral
proteins are expressed through the resulting mRNA. Copies of the negative-strand RNA are
also made and packaged into ribonucleoprotein complexes for packaging into new viruses.
(v) Assembly and release: The viruses assemble, bud, and are released from the cell
membrane. NA cleaves sialic acids from the cell surface proteins to release the virions from
the host cell (7). Figure adapted with permission from Nature Publishing Group (18).
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1.2 Treatment and Prophylaxis for Influenza A Virus
1.2.1 Licensed prophylactics and treatment
There are currently two distinct strategies in use to control the spread of influenza:
vaccines and conventional small-molecule antiviral drugs. Vaccination with the trivalent
inactivated or live attenuated vaccines offers only limited protection (19), and is hampered
by logistical issues, such as prediction of future circulating strains, and reliability of supply
(7). In the event of a pandemic, rapid production of sufficient quantities of vaccine can be a
challenging task (20). Antivirals present an attractive alternative, and can potentially
inhibit viruses of different subtypes or genetic variation. There are four clinically approved
antivirals for influenza treatment and prophylaxis (Figure 3). Amantadine and rimantadine
are inhibitors of the M2 ion channel, and interferes with viral fusion (21). Zanamivir (ZA)
and oseltamivir inhibit NA enzymatic activity, thus blocking the release of newly made
virions from infected cells (22, 23). Despite their efficacy, these antivirals suffer from
limitations such as a short therapeutic window, high dosage, side effects, and high costs
(18, 24, 25). In addition, all the circulating viruses (both H3N2 and H1N1 strains) are
already resistant to the M2 inhibitors (26-28), and resistance to the NA inhibitors has been
appearing at an alarming rate in recent years (12, 28).
1.2.2 Investigational Antivirals under Clinical Trials
In response to the need for potent new antivirals to bolster our defense against
influenza, there has been intense focus in both academia and industry to identify novel
15
Chapter 1: Introduction
candidates for influenza therapy. Candidates currently undergoing clinical trials will be
discussed herein.
NA inhibitors
Two additional NA inhibitors, peramivir (29, 30) and laninamivir (31), have been
identified for treatment and prophylaxis for influenza (Figure 3). During the recent 2009
H1N1 pandemic, the US Food and Drug Admistration (FDA) even had to issue an
Emergency Use Authorization for intravenous peramivir in cases where current therapy
were ineffective or unavailable (32). Nonetheless, since peramivir also inhibits NA, cross-
resistance has already been observed with some oseltamivir- and ZA-resistant strains (33).
Laninamivir is structurally related to ZA, with the advantage of a longer half-life. A single
dose of inhaled laninamivir has been shown to be comparable to a standard course of
oseltamivir in the elderly in reducing the time of recovery (34). However, the activity of
laninamivir against existing oseltamivir- or ZA-resistant viruses and its own resistance
profile however remains largely unknown.
Polymerase inhibitors
Other influenza antiviral drugs under clinical trials include inhibitors of
transcription and genome replication, T-705 (favipiravir) (35, 36) and ribavirin (37)
(Figure 3). T-705 is a pyrazinecarboxamide derivative, and its active form, T-705-4-
ribofuranosyl-5'-triphosphate, has been postulated to selectively inhibit the influenza RNA-
dependent RNA polymerase (38). T-705 has been shown to inhibit both oseltamivir- or
amantadine-resistant 2009 H1N1 influenza at pM concentrations, however, it is
16
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unexpectedly much less effective against dually resistant viruses (39). In addition, there are
few published data on resistance to T-705 (9).
Ribavirin inhibits the host cellular enzyme inosine 5'-monophosphate
dehydrogenase, a key enzyme in GTP biosynthesis and viral RNA synthesis (18). Besides
limitations in the design of the clinical trials for ribavirin (40), data from animal studies
and clinical trials has been inconsistent with the observed in vitro anti-influenza efficacy
(37, 41). In recent years, influenza-related ribavirin studies have mostly focused on
investigating ribavirin as an adjunct in combination therapy (42-44).
Host targeting inhibitors
A search on the ClinicalTrials.gov website with key words 'influenza' and 'antivirals'
reveal that all other candidates under clinical evaluation target host factors (45). DAS181
(FludaseTM) is a fusion sialidase that can be inhaled to remove the viral receptor sialic acid
from the airway epithelium, thus preventing the attachment of influenza virus onto host
cells (46). DAS181 has shown broad-spectrum anti-influenza activity (47-49), but some
unstable resistant mutants have been identified in drug selection experiments (personal
communication from the developers of DAS181, cited in (9)).
Liposome-encapsulated polyinosinic-polycytidylic acid (Poly-ICLC), first discovered
40 years ago (50), is being revisited as a possible way to control influenza infection. Poly-
ICLC activates the host immunity to fight influenza virus infections (51), likely by inducing
the expression of immune factors like toll-like receptor 3, interferon, and cytokines (52).
Yet, much care has to be exercised with optimizing the administration regime (patient
17
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selection and dosage) as serious side effects has been reported in humans and animal
models (53-56).
1.2.3 Conclusion
The antiviral drugs under clinical development look promising. Nevertheless, it is
expected that resistant strains will eventually develop if these antivirals are used as
monotherapy clinically, as that observed with the M2 and NA inhibitors (57). The
emergence of drug resistance in seasonal and pandemic influenza viruses in recent years
remind us not to rest on our laurels; especially given the unpredictability of this pathogen
and the paucity of options in controlling its spread. Particular emphasis should be placed
on exploring combination therapy, and developing novel antivirals with a different
mechanism of action that can significantly reduce drug resistance (58, 59).
18
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Figure 3. Antiviral inhibitors. Structures of (i) M2 inhibitors amantadine and
rimantadine; (ii) NA inhibitors zanamivir, oseltamivir, peramivir, and laninamivir; and (iii)
inhibitors of transcription and genome replication ,T-705 and ribavirin.
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1.3 Motivation for this thesis and thesis outline
Facing the challenges mentioned above- limitations of current therapeutics, rapid
spread of drug resistance, and the looming threat of the next pandemic- we have
established a new strategy to develop potent influenza antivirals that can significantly
minimize drug resistance. The strategy is based on (i) the observation that attaching
monomeric inhibitors to a polymer makes them much more potent (60), and (ii) the
principle of combination therapy, where two or more distinct targets are inhibited. Small
molecular weight inhibitors covalently conjugated to a biocompatible polymer have been
reported to inhibit human influenza strains (61), and prevent influenza binding of red
blood cells (62, 63).
My thesis work is based on our lead candidate, ZA covalently attached via a flexible
linker to water-soluble, biodegradable poly-L-glutamine (PGN), hereforth termed as PGN-
ZA (Figure 4). We have previously shown that PGN-ZA was 1,000- to 10,000-fold more
potent than monomeric ZA in plaque reduction assays, and importantly, PGN-ZA remains
effective against both ZA- and oseltamivir-resistant influenza viruses (64). We have also
shown that attaching two different inhibitors, ZA and sialic acid, onto the same polymeric
chain further enhances antiviral potency (65). My work will be divided into the following
two chapters in this thesis:
1) Polymer-attached zanamivir synergistically inhibits both early and late steps of
influenza virus infection
In Chapter 2, 1 present results on elucidating the mechanism of action underlying
the dramatically increased antiviral potency of this polymeric inhibitor. I will show that,
similar to monomeric ZA, the polymeric inhibitor binds specifically to viral NA and inhibits
20
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its enzymatic activity and the release of newly synthesized virions from infected cells. By
using time-of-addition assays, I will also show that, in contrast to the monomeric ZA, the
polymer-attached drug also synergistically inhibits an early step of influenza virus
infection, accounting for the dramatically increased antiviral potency. By exploring each
step of early virus replication, I will show that the inhibition of the early step of influenza
infection is not by direct virucidal effect, aggregation of viruses, or inhibition of viral
attachment to target cells and the subsequent endocytosis, but rather is due to inhibition of
virus-endosome fusion.
2) Polymer-attached zanamivir delays the emergence of influenza drug resistance
In Chapter 3, I present the findings on investigating the ability of the multivalent drug
conjugate to minimize drug resistance. By passaging influenza virus in vitro under drug
selection pressure, I will show that the PGN-ZA is able to significantly delay the emergence
of drug resistance compared to monomeric ZA. This will be further supported genotypic
and phenotypic characterization of variant viruses selected under PGN-ZA and monomeric
ZA drug pressure.
1.4 Significance
All current antivirals have only one mechanism of action, and the rapid emergence
of drug resistance amongst circulating influenza strains is a major health concern (28, 58,
59), highlighting the urgent need for development of novel influenza antivirals that can
minimize drug resistance. The thesis presents new mechanistic information and drug
resistance profile for polymer-attached ZA, the lead candidate in our influenza drug
development work. The data in the subsequent chapters will show, for the first time, a
21
Chapter 1: Introduction
single antiviral drug with dual synergistic mechanisms of inhibition, and the ability to delay
the emergence of drug resistance. Results from Chapter 3 also indicate the potential use of
polymer-attached drugs as tools to identify critical amino acids involved in certain viral
processes, and to better understand the essential balance between HA and NA functions in
viral replication. These findings provide new insight on the design of influenza antivirals
and further validate polymer-attached inhibitors as a new framework of drug development
in overcoming drug resistance.
22
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HN-(CH2)6 NH2
0
H0
H3COCHN,
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x/(x+y) = 0.10
ZA-linker -N
H
Polymer-attached ZA
Figure 4. Zanamivir derivatives. Structures of monomeric ZA derivative (ZA-linker) and
multivalent polymer-attached ZA (PGN-ZA) are shown as above. PGN-ZA used in the
following two chapters of the thesis has 10% degree loading.
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Chapter 2
POLYMER-ATTACHED ZANAMIVIR INHIBITS SYNERGISTICALLY
BOTH EARLY AND LATE STEPS OF INFLUENZA VIRUS
REPLICATION
Abstract
Covalently conjugating multiple copies of the drug zanamivir (ZA) (the active ingredient in
RelenzaTM) via a flexible linker to poly-L-glutamine greatly enhances the anti-influenza-
virus activity. In this study, we have elucidated the mechanism of this phenomenon. Like ZA
itself, the polymer-attached drug binds specifically to viral neuraminidase and inhibits both
its enzymatic activity and the release of newly synthesized virions from infected cells. In
contrast to monomeric ZA, however, the polymer-attached drug also synergistically
inhibits an early step of influenza virus infection, thus contributing to the dramatically
increased antiviral potency. This inhibition is not caused by a direct viricidal effect,
aggregation of viruses, or inhibition of viral attachment to target cells and the subsequent
endocytosis, but rather is due to reducing the virus-endosome fusion. These findings
rationalize the enhanced anti-influenza potency of polymer-conjugated ZA and reveal that
attaching the drug to a polymeric chain confers a new mechanism of antiviral action
potentially useful for minimizing drug resistance.
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Introduction
Influenza A viruses cause epidemics and pandemics in human populations, inflicting
enormous suffering and economic losses (1). Currently, two distinct strategies - vaccines
and small-molecule drugs - are utilized to control the spread of influenza (1). Vaccination
offers limited protection and is hampered by logistical challenges, such as accurate
prediction of future circulating strains and production of sufficient quantities of vaccine for
large populations within a short time (2, 3). Two of the four antiviral drugs approved in the
United States for the treatment and prophylaxis of influenza, amantadine and rimantadine,
inhibit the viral M2 ion channel protein (4), while and the other two, zanamivir (ZA) and
oseltamivir, inhibit the viral neuraminidase (NA) activity (5, 6). These drugs have limited
therapeutic windows, side effects, and high costs (7-9), and most circulating viruses are
already resistant to the M2 inhibitors (10, 11). Furthermore, resistance to the NA inhibitors
is spreading rapidly (12, 13). Thus, the need to develop novel influenza therapeutics that
can prevent viral resistance or significantly reduce its incidence is urgent (14, 15).
An alternative approach to conventional antivirals is the use of multivalent
polymeric inhibitors (16). In particular, small-molecule inhibitors covalently conjugated to
a biocompatible polymer have been reported to inhibit human influenza strains (17) and
prevent influenza binding to red blood cells (18, 19). We have previously shown that the
antiviral efficacy of ZA is dramatically enhanced when multiple copies thereof are attached
via a flexible linker to the benign and biodegradable polymer poly-L-glutamine (PGN) (20):
the resultant PGN-ZA is 1,000- to 10,000-fold more potent than monomeric ZA in plaque
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reduction assays and, importantly, is effective even against ZA- and oseltamivir-resistant
influenza viruses.
Herein we have elucidated the mechanisms underlying the dramatically higher
antiviral potency of this multivalent drug conjugate. We show that, like ZA itself, PGN-ZA
binds to NA and inhibits its activity and the release of newly synthesized virions from the
infected cells. In addition, PGN-ZA inhibits virus-endosome membrane fusion during initial
virus infection. Thus attaching ZA to PGN results in a new mode of drug action. The
synergistic inhibition of both the early and late steps of influenza virus infection accounts
for the markedly enhanced antiviral potency of PGN-ZA compared to the monomeric ZA
precursor.
Results
PGN-ZA binds to and inhibits viral NA
Influenza virus has two main surface glycoproteins, hemagglutinin (HA) and NA
(21). Both of them bind to the terminal sialic acid of cell-surface glycans (22-24). Since ZA
is a sialic acid (SA) derivative and inhibits the enzymatic activity of NA, we sought to (i)
determine why its conjugation to PGN via a flexible linker raised its binding and inhibitory
activities and (ii) exclude non-specific effects by the PGN chain itself. To characterize
binding of PGN-ZA to whole virions, we performed whole-virus ELISA binding assays
where PGN-ZA or PGN were immobilized to 96-well plates by UV cross-linking, incubated
with influenza A/WSN33 (H1N1) (WSN), and then quantified using HRP-conjugated anti-
H1 antibodies. PGN-ZA exhibited a concentration-dependent binding with saturation to the
31
Chapter 2: PGN-ZA inhibits synergistically both early and late steps of influenza virus replication
whole H1N1 viruses in the therapeutic range, as determined by plaque reduction assays
(Figure 1A), whereas PGN itself showed no significant virus binding under the same
conditions.
We examined PGN-ZA's specific site of action by measuring its binding to purified
HA and NA proteins by means of ELISA. The polymer-attached drug displayed a dose-
dependent binding to NA, but not to HA (Figures 1B, 1C, and Si). In contrast, multivalent
polymeric SA conjugates (PGN-SA) exhibited specific binding to HA, as SA is the cognate
ligand of HA (Fig. 1C). PGN by itself did not bind to either HA or NA. PGN-ZA was 3- and 10-
fold more potent than ZA modified with the linker (ZA-linker) (ZA-linker's antiviral activity
is similar to that of ZA itself (20)) in inhibiting NA activity of WSN and influenza
A/PR/8/34 (PR8) viruses, respectively (Table 1). These data indicate that bare PGN has no
appreciable interaction with HA, NA, or whole virions and that PGN-ZA specifically binds to
NA and inhibits its enzymatic activity.
PGN-ZA synergistically inhibits both early and late steps of influenza virus infection
Since PGN-ZA inhibits NA, as does the monomeric ZA, we expected PGN-ZA to inhibit
the release of newly synthesized virions. MDCK cells were infected at a multiplicity of
infection (moi) of 2. Because newly synthesized viruses were released after about 4 h, PGN-
ZA and ZA-linker were added 3 h post-infection (p.i.) to restrict inhibitory activity to the
late phase of virus replication (Figure 2A). At 7 h p.i., the culture supernatant was
harvested, and the viral titer was measured by the plaque assay. Compared to the PBS
control, addition of PGN-ZA and ZA-linker reduced the virus titer by some 90% and 80%,
respectively (Figure 2B). To control for the presence of leftover inhibitors in the collected
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supernatants (albeit at concentrations below IC50 upon serial dilution), some PBS control
samples were spiked with the same concentration of PGN-ZA just prior to the plaque assay.
No significant reduction of virus titer was detected in those cases compared to the PBS
control, confirming no interference from low concentrations of inhibitors remaining in the
supernatants. These results show that PGN-ZA specifically inhibits the release of newly
synthesized viruses from infected cells.
To test whether PGN-ZA inhibits early events of influenza virus infection, we
performed time-of-addition experiments in a single-cycle infection (Figure 3A). MDCK cells
were infected with WSN virus at a moi of 20, and the inhibitors were added at different
time points p.i.: -1 h, 0 h, or 1 h. The cell culture supernatants were harvested at 3 h p.i.
before the completion of a single infection cycle. The cells were fixed, and expression of the
viral proteins NP and M1 was quantified by flow cytometry. The fraction of infected cells
decreased by 30-50% upon the addition of PGN-ZA (Figure 3B). In contrast, for all the
conditions tested, ZA-linker did not affect the fraction of cells infected. Thus PGN-ZA,
unexpectedly, also specifically inhibits an early step of influenza virus infection.
To explore the relationship between PGN-ZA's inhibitory effects in the early and late
steps of virus infection, we performed a time-of-addition plaque assay with the avian strain
A/Turkey/MN/80 (TKY). The inhibitors were added in different time points of the assay:
(i) early (-1 to 1 h p.i.), (ii) late (1 to 72 h p.i.), or (iii) both early and late (-1 to 72 h p.i.).
When added during the late phase of plaque assay, PGN-ZA significantly reduced the
number of plaques with an IC5o of 14.8 nM (Figure 4). Remarkably, when the virus was
exposed to PGN-ZA throughout the assay in both the early and late stages, the potency of
PGN-ZA rose almost 100-fold to an ICso of 0.16 nM. The IC5o values for the monomeric ZA
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and ZA-linker remained the same under both conditions, thereby revealing no additional
benefit from introducing the monomeric inhibitors in the early phase of the infection. As
expected, a reduction in the IC50 values was also associated with a reduction in the sizes of
the plaques (data not shown).
Taken together, the foregoing results indicate that (i) the multivalent PGN-ZA
potently inhibits at least two distinct steps in influenza infection: an event early during the
infection process, as well as the release of newly synthesized virions; (ii) monomeric ZA
inhibits only virus release, and (iii) PGN-ZA's dual mechanism of action produces a
synergistic inhibition of virus replication.
PGN-ZA inhibits influenza infection through neither direct virucidal effect nor virus
aggregation
PGN-ZA can inhibit an early step of influenza virus infection through a direct
viricidal effect and/or by aggregating viruses and thus preventing them from infecting
target cells. To test these mechanisms, we used transmission electron microscopy (TEM)
imaging to look for changes in viral envelope integrity and morphology upon PGN-ZA
treatment. Purified WSN virus was filtered through a 0.2-prm filter and treated with either
PGN-ZA or PBS for 1 h prior to staining with uranyl formate, followed by TEM imaging. As
seen in high-magnification micrographs, PGN-ZA did not affect the morphology or envelope
integrity of viral particles (Figure 3A, lower panel). In addition, low-magnification
micrographs (Figure 5A, upper panel) were taken to determine the distribution of viral
particles in clusters. From over 5,000 viral particles analyzed, no significant increase was
observed in virus aggregation (clustering of two or more viruses together) upon PGN-ZA
treatment (Figure 5B), consistent with dynamic light scattering results (Figure S2). To rule
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out staining artifacts, phosphotungstic acid was also used to visualize the samples, and the
data obtained corroborated those of the uranyl formate-stained samples (Figure 6). Thus,
somewhat surprisingly, inhibition of the early step of influenza infection by PGN-ZA is not
through a direct virucidal effect or aggregation of viral particles.
PGN-ZA does not affect virus attachment and endocytosis
To examine whether PGN-ZA affects virus binding and endocytosis, we performed a
flow-cytometry assay using labeled antibodies against viral NP and M1 (Figure 7A). Virus
attachment was measured by incubating WSN virus at moi of 20 with MDCK cells at 4*C, at
which temperature endocytosis does not occur (Fig. 7A, Group I). To assay for endocytosis,
the same cells were incubated at 37*C for 30 min to allow the surface-bound virions to be
endocytosed. Bacterial sialidase was later introduced into the system to remove surface-
bound virions (Fig. 7A, Groups II and IV). Since internalized viruses are protected from
sialidase activity, any cell-associated virus remaining after the sialidase treatment would
presumably be that which has been internalized (Fig. 7A, Group IV). As shown in the left
panel of Figure 7B, PGN-ZA did not inhibit virus binding to MDCK cells. Expectedly, there
was a significant drop in virus-associated cells following sialidase treatment (Fig. 7B, Group
II). PGN-ZA also did not affect virus endocytosis, as evidenced by the similar levels of virus-
associated cells with or without sialidase treatment of 37*C-incubated cells (Fig. 7A, Groups
III and IV). Statistical analysis of all four sets of conditions confirmed that the presence of
PGN-ZA does not affect virus attachment and internalization (Figure 7C). Hemagglutination
inhibition assays also revealed that PGN-ZA did not affect virus binding to red blood cells
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(Figure S3). These results indicate that PGN-ZA does not inhibit binding or endocytosis of
influenza virus infection.
PGN-ZA inhibits virus-endosome fusion
To investigate PGN-ZA's effect on influenza virus fusion, we imaged individual viral
particles in MDCK cells fixed at different time points p.i. by using fluorescence microscopy.
The WSN virus was labeled with amine-reactive Alexa Fluor 647 dye; the virus retained
infectivity and binding to red blood cells (data not shown). To synchronize infection, the
viruses were first incubated with MDCK cells on ice for 60 min in the absence or presence
of PGN-ZA. The mixture was then rapidly warmed to 37*C to initiate infection. After the
start of infection, virus fusion begins at about 10 min, with approximately two-thirds of the
viruses being fusion-defective (25). The MDCK cells were then fixed at 0, 5, or 15 min p.i.
and stained (Figure 8A). No apparent difference in the abundance of labeled viral particles
was observed between the samples with or without PGN-ZA at t = 0 min, concordant with
the results of the flow cytometry-based binding experiments (Fig. 7B). At t = 15 min, a
significant accumulation of viral particles was observed in the perinuclear region with the
PGN-ZA-treated samples, as compared to the PBS control (Figure 8B). Since approximately
one-third of the viruses in the PBS control are able to undergo fusion, the observed viral
particle accumulation in the PGN-ZA sample at 15 min would reflect a block of fusion by
some 85%.
When an influenza virus is exposed to an acidic environment, most HA subtypes
undergo a pH-induced conformational change. In the presence of a membrane, fusion
occurs; in the absence of a membrane, the HA is irreversibly inactivated abolishing the viral
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infectivity (26). To investigate the ability of PGN-ZA to inhibit this process, the TKY virus
was incubated at pH 5 in the presence or absence of PGN-ZA at 37*C for 15 min. The level of
infectious virus remaining after this acidic treatment was determined by serial titrations
using the plaque assay. PGN-ZA blocked the pH-5-induced inactivation of virions 2-3 fold
compared to the PBS control (Figure 9). In contrast, the viral titer did not change following
a pH 7 incubation (Figure S4). These results indicate that PGN-ZA inhibits the early steps of
influenza infection by interfering with virus-endosomal membrane fusion.
Discussion
In this report, we have investigated the mechanism underlying the greatly enhanced
antiviral potency of a polymer-attached zanamivir. Compared to its small-molecule
predecessor, PGN-ZA is three to four orders of magnitude more potent in inhibiting
influenza virus infection, as determined by plaque reduction assays (20). We have found
that, like ZA, PGN-ZA specifically binds to NA and inhibits its enzymatic activity and the
release of the newly synthesized viruses from infected cells. PGN-ZA is more potent in
inhibiting virus release than ZA itself, likely due to an increased avidity to NA from polymer
binding and hence an increased inhibition of NA's activity. While inhibition of virus release
by PGN-ZA was expected, the observation that PGN-ZA also inhibits an early step of
influenza infection is surprising. Compared to the inhibition of virus release, which reduces
virus titer by over 90% (Fig. 2B), inhibition of the early step of influenza infection by PGN-
ZA lowers infection by 30-50% (Figure 3B), indicating that the former process is still the
dominant mechanism of inhibition. More importantly, the two antiviral mechanisms act
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synergistically (Figure 4), accounting for the greatly enhanced (-1,000 fold) antiviral
potency of PGN-ZA over monomeric ZA.
Our observations afford further mechanistic insights. A PGN-ZA-induced viral
aggregation may lead to a direct virucidal effect or interfere with infection. However, we
detected no obvious deformation of virus integrity or significant aggregation of viruses
caused by PGN-ZA. Nor did we see any significant effect of PGN-ZA on attachment of viruses
to cell surface and their subsequent endocytosis into target cells. What we did observe was
the prolonged accumulation of viruses in the perinuclear region. Normally, following
exposure to the low pH in the endosomes, viral HA undergoes a conformation change
leading to fusion of the viral envelope with the endosomal membrane and subsequent
release of viral genome into the cytosol (27). The unexpected observation that PGN-ZA
inhibits virus-endosome fusion is further supported by our finding that PGN-ZA protects
influenza virus from low pH-induced inactivation. Therefore, although PGN-ZA does not
interact with HA directly (Figure 1), its interaction with NA somehow prevents HA from a
pH-induced conformation change and, in turn, virus-endosome fusion. To our knowledge,
this is the first report showing that attaching monomeric inhibitors to a polymeric
backbone confers new mechanisms of action.
How does PGN-ZA inhibit virus-endosome fusion? Influenza viruses have 300-500
HA and 30-50 NA per virion (27). HA is required for viral attachment to cell surface glycan
receptors, as well as virus-endosome fusion (28). Our finding that virus attachment to
target cells and endocytosis are not affected by PGN-ZA is consistent with no interaction
between PGN-ZA and HA, as measured by ELISA. Although ZA has been reported to inhibit
fusion of HA-expressing cells with erythrocytes, the experiment was performed with 2-10
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mM of ZA, which is some 10s- to 106-fold higher than the therapeutic range used in our
study (29). Therefore, the effect of PGN-ZA on HA is probably indirect. It is possible that the
multivalent binding of PGN-ZA to NA blocks the conformational change of HA through
steric hindrances without affecting HA binding to surface glycan receptors. It is more likely,
however, that NA is directly involved in virus-endosome fusion. A role of NA in early virus
infection is less clear and defined than its essential function in virus release. Although it has
been suggested that viral NA plays a role in early infection by removing SA in mucin to
allow virions to reach the lung epithelial cells (30, 31) and/or enhancing late
endosome/lysosome trafficking (32), other studies suggest that NA is not required for virus
entry, replication, or assembly (33). Because inhibition of the early step of influenza
infection contributes less than inhibition of virus release to overall reduction of infection,
the virus-endosome fusion may be less dependent on NA activity. As a result, while not
inhibited by less potent monomeric ZA, this fusion event is inhibited by the more potent
polymeric inhibitor PGN-ZA.
All existing influenza antivirals have only one mode of action, and a rapid emergence
of drug-resistant variants is a major public health challenge in the control of influenza (13-
15). The data presented here show that PGN-ZA can synergistically inhibit both viral fusion
and release at sub-nM concentrations of ZA. This dual mechanism of inhibition is novel
among known influenza antivirals and consistent with our previous observation that PGN-
ZA remains effective against ZA- or oseltamivir-resistant influenza virus isolates (20).
Multivalent antivirals thus offer an alternative to conventional combination therapy by not
only protecting against influenza virus infection but also minimizing the emergence of drug
resistance.
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Materials and Methods
Inhibitors.
Poly-L-glutamic acid (molecular weight of 50,000-100,000 Da) and all other
chemicals, biochemicals, and solvents were from Sigma-Aldrich Chemical Co. (St. Louis,
MO). 4-Guanidino-Neu5Ac2en (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic
acid) was purchased from Bioduro (Beijing, China). The ZA-linker derivative was
synthesized as described previously (34). PGN-ZA and the bare PGN were prepared from
poly-L-glutamic acid and characterized as described previously (20). Concentrations of
inhibitors used in the mechanistic studies were 100 x ICso, unless indicated otherwise.
Viruses and cells.
Influenza virus A/WSN/33 (WSN), subtype H1N1, was kindly provided by Dr. Peter
Palese (Mount Sinai School of Medicine, New York City). Influenza A/Turkey/MN/80 (TKY),
subtype H4N2, was obtained from the Centers for Disease Control and Prevention (Atlanta,
GA). Influenza A/PR/8/34 virus was purchased from Charles River Laboratories
(Wilmington, MA). The WSN virus was cultured in Madin-Darby canine kidney (MDCK)
cells from the ATCC. The cells were routinely passaged in Eagle's minimal essential medium
(MEM) containing 10% fetal bovine serum. The A/Turkey/MN/80 virus was propagated in
11-day-old embryonated chicken eggs. The grown viruses were clarified by low-speed
centrifugation and concentrated before sucrose gradient purification using a Beckman
SW41 rotor at 24,000 rpm. Viruses were resuspended in phosphate-buffered saline (PBS)
and stored at -80'C.
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Virus binding assay and HA/NA specificity assays.
ELISA to measure the direct binding activity of influenza A/WSN/33 virus was
performed using a modified literature procedure (35). Briefly, microtiter plates (Corning
Polystyrene Universal-BIND Microplate, Corning, NY) were incubated with 50 pL of varying
dilutions of the multivalent inhibitor in PBS at 4*C overnight and irradiated with 254-nm
UV light for 5 min. The solution was then aspirated, and the plates were washed thrice with
2% BSA (Sigma) and 0.05% (v/v) Tween 20 in PBS (PBST), followed by a further 3-h
blocking step with 0.3 mL of PBST at RT. The plates were then washed thrice each with
PBST and 2% BSA in PBS (PBS-BSA), followed by incubation with a solution containing
influenza virus in PBS-BSA at 4*C overnight. Polyclonal antibodies to the virus diluted in
PBS-BSA were subsequently added to the plates and incubated for 5 h at 4*C. The plates
were then washed with PBS-BSA thrice and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies in PBS-BSA for 2 h at 4*C. The plates were washed as
above with PBS-BSA before addition of substrate. Colorimetric development of 50 ptL of 1-
Step Ultra TMB (Thermo Scientific) at RT was stopped with 50 p.L of 0.2 M H2SO 4 after
incubation for 30 min, and the absorbance was determined at 450 nm.
For the HA/NA binding specificity assays, the microtiter plates were covalently
conjugated with 50 pL of 10 ig/mL polymeric inhibitor and blocked as above. For the HA
specificity assay, His-tagged A/WSN/33 (H1N1) HA protein (eEnzyme, Gaithersburg, MD),
primary (mouse anti-His tag IgG, Abcam, Cambridge, MA), and secondary (HRP-conjugated
goat anti-mouse IgG, Biolegend, San Diego, CA) antibodies were mixed in the ratio 4:2:1 and
incubated on ice for 20 min. Likewise, His-tagged A/Cal/04/2009 (HiN1) NA (Sino
Biological, Beijing, China), primary and secondary antibodies were mixed in the ratio 4:2:1,
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and incubated on ice for 20 min in the NA specificity assay. The mixtures of pre-complexed
HA or NA were then diluted to varying concentrations with PBS-BSA, and 50 ptL was added
to each well and incubated for 2 h at RT. The wells were washed four times with PBST, and
HRP activity was measured as in the whole virus binding assay above. The experiment was
repeated with varying dilutions of the multivalent inhibitor conjugated to the plate, with
concentrations of the pre-complexed proteins constant at 5 ptg/mL.
NA inhibition assay was performed and analyzed as described previously (20). Briefly, 20
ptL of virus and 15 ptL of inhibitor dilutions were pre-incubated for 1 h at RT. The
fluorogenic NA substrate 4-methylumbelliferyl-a-D-N-acetylneuraminic acid (at a
concentration of 3-4 pM) was added, and the enzyme kinetics was measured by monitoring
the generation of 4-methylumbelliferone for 1 h. Values of Ki were determined with nonlinear
regression.
Virus release assay.
MDCK cells were incubated with the WSN virus on ice for 60 min to allow binding,
and the cells were washed thrice with PBS to remove unbound virus. The cells were then
moved to 37*C to begin the infection process. After 3 h p.i., the infection media was
replaced with that containing either PGN-ZA, ZA-linker, or PBS. After 4 h, the supernatant
was harvested, and the viral titer quantified by virus plaque assay.
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Flow cytometry.
To quantify single-cycle infection by flow cytometry, MDCK cells were infected with
WSN virus at moi of 20 for 1 h on ice, followed by washing thrice with ice-cold PBS to
remove unbound virus. Infection medium was then added and the temperature raised to
37*C to allow infection to begin. The inhibitors were added at -1, 0, or 1 h p.i. To remove
them, the cells were washed 4 times with pre-warmed PBS. Mock-infected and WSN-
infected/untreated (PBS) samples acted as controls. At 3 h p.i., the MDCK cells were
trypsinized, washed with PBS twice, and fixed with 2% paraformaldehyde in PBS. The fixed
cells were washed with PBS containing 2% FBS (PBS-FBS) twice and resuspended in 0.1%
saponin in PBS-FBS (permeabilization buffer). After 10 min at RT, the samples were
centrifuged and resuspended in 80 tL of the permeabilization buffer containing 1 pg/mL
anti-NP (AbD Serotec, Raleigh, NC) and anti-Mi (Abcam) monoclonal antibodies. Following
a 1-h incubation in the dark at RT, unbound antibodies were removed by two washes with
1 mL of the permeabilization buffer. The cells were then incubated with 50 p1 of
phycoerythrin-linked anti-mouse IgG antibody (Biolegend) for 30 min at RT. Unbound
antibodies were again removed by two washes of 1 mL of the permeabilization buffer.
Finally, the cell pellets were resuspended in PBS-FBS and analyzed on the Accuri C6 flow
cytometer. The analytical gatings between infected and uninfected cells were determined
from the PE fluorescence intensity histograms of the mock-infected negative controls. The
extent of influenza infection was quantified as the fraction of cells with fluorescence
intensity above the analytical gating. All samples were normalized to the mean of 3
infected, untreated (PBS) controls.
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For the flow cytometry-based binding and internalization studies, MDCK cells were
trypsinized, resuspended in DMEM, and exposed to WSN virus at moi of 20 on ice for 1 h.
For internalization studies, the cells were then moved to 37*C for 30 min to allow
endocytosis of the bound virions. To differentiate between internalized and surface-bound
virions, bacterial sialidase was introduced to remove surface-bound virions. The cells were
washed twice with DMEM to remove unbound viruses and inhibitor and treated with
Arthrobacter ureafaciens (20 mU/100 pL) and Vibrio cholera (25 mU/100 ptL)
neuraminidase for 1 h at 37*C. For subsequent flow cytometry analysis, the cells were
fixed, processed, and analyzed as described above.
Virus plaque assays were performed using a modified literature procedure (20, 36, 37).
Briefly, for the early-stage inhibition samples (-1 to 1 h), equal volumes of viruses and
inhibitors of various concentrations were pre-incubated for 1 h prior to cell inoculation.
Thereafter the inoculum was aspirated, and the cells were washed 4 times with pre-
warmed PBS to remove any residual inhibitor or viruses. The cells were then overlaid with
agar solution with no inhibitor. In the case of the late-stage inhibition samples (1 to 72 h),
there was no pre-treatment, and the initial 1-h infection was also done in the absence of
inhibitors. After infection, the cells were overlaid with agar solution containing the
appropriate concentrations of inhibitor. For the combination samples (-1 to 72 h), the
inhibitor was present throughout the assay, from pre-treatment through the agar overlay.
44
Chapter 2: PGN-ZA inhibits synergistically both early and late steps of influenza virus replication
Transmission electron microscopy (TEM).
The WSN virus was sonicated, and remaining viral aggregates were removed using a
0.2-ptm-pore filter. The virus was then incubated at RT for 1 h with either PBS or PGN-ZA at
a concentration exceeding 10 x ICso. The surface of a carbon/formvar film supported on a
Cu grid was treated with a drop of the influenza virus solution for 1 min. The surface was
washed by successively dipping the grid in 3 drops of water and stained with either 0.75%
uranyl acetate or 1% phosphotungstic acid. A drop of the stain was placed on the surface of
the grid for 45 s and then removed by absorption onto a piece of filter paper. The samples
were allowed to dry overnight and analyzed using a Tecnai G2 Spirit Biotwin TEM
instrument.
Fluorescence microscopy.
The labeling process was modified from a published protocol (25). The WSN virus
was labeled with Alexa Fluor 647 carboxylic acid succinimidyl ester dye (Invitrogen, Grand
Island, NY) in a carbonate buffer (pH 9.3) at RT for 1 h with gentle shaking. Unbound dye
was removed by a buffer exchange with 50 mM Hepes buffer (pH 7.4, 145 mM NaCl) using
NapS gel filtration columns (GE Healthcare, Waukesha, WI). Viral aggregates were
removed by filtration immediately prior to experiments using a 0.2-pm filter. MDCK cells
were exposed to the dye-labeled WSN at moi of 20 on ice for 1 h to allow binding. Unbound
virus and inhibitors were removed by 3 washes of cold PBS, and the samples were
immediately moved to a 37'C water bath to begin infection. Samples were washed, fixed at
0, 5, and 15 min p.i. with 2% paraformaldehyde, and cured overnight with DAPI Prolong
Gold (Invitrogen). Images were taken on Applied Precision DeltaVision Ultimate Focus
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Microscope with a 60x objective. The images taken were deconvolved to visualize
individual virus peaks. For quantitative analysis, the number of viruses per cell was
quantified using ImageJ and normalized to the PBS controls.
Inactivation of virus by acidic treatment.
The low-pH inactivation of influenza virus was performed as previously described
(38), and the virus was titrated with the plaque assay.
Statistical Analysis was performed using two-tailed t-tests (39).
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Figures and Tables
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Figure 1. PGN-ZA binding to influenza virus. PGN-ZA and PGN were first covalently
attached to 96-well plates via UV cross-linking. The relative binding of whole influenza
A/WSN/33 virions (A), and the two major influenza surface proteins, NA (B) and HA (C), to
the inhibitors were determined using ELISA assays. Bare PGN was included as a control of
non-specific binding and PGN-SA as a positive control for HA binding. Error bars represent
the standard errors of means (SEM) from two independent experiments.
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Figure 2. PGN-ZA inhibits the release of newly synthesized viruses from infected
cells. (A) Experimental design to detect the release of newly synthesized viruses from
infected cells. (B) MDCK cells were inoculated with WSN virus in a synchronized infection,
and unbound virus was then removed. The inhibitors were added 3 h p.i. The supernatant
was collected at 7 h p.i., serially diluted, and titrated using the plaque assay. As a control for
any remaining inhibitor in the plaque assay, some PBS controls were spiked with the same
concentration of PGN-ZA and titrated in parallel with the original PBS controls. Error bars
in B represent standard errors of means (SEM) from 3-4 independent experiments.
*p<0.05; **p<0.01.
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Figure 3. PGN-ZA inhibits an early step of influenza virus replication. (A) Scheme of
time-of-addition experiment to assay inhibition in the early phase of virus infection in a
single replication cycle assay. (B) MDCK cells were infected with WSN, and the inhibitors
were added in at -1, 0, or 1 h p.i.. The cells were trypsinized, fixed at 3 h p.i., stained for
intracellular viral NP and M1, and analyzed by flow cytometry. The gating for virus-infected
cells was drawn based on the expression level of a mock-infected control, and the fraction
of the cells infected was normalized to the untreated, infected sample. Error bars in B
represent standard errors of means (SEM) from 3-5 independent experiments. ***p <
0.001.
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Figure 4. PGN-ZA synergistically inhibits early and late steps of influenza virus
infection. MDCK cells were infected with A/Turkey/MN/80, and the inhibitors were added
either -1 to 1 h p.i. or 1 to 72 h p.i. The bars represent IC50 values, i.e., the concentration of
inhibitor reducing the plaque number in untreated controls by half. For the samples in the -
1 to 1 h condition, the ICsos are higher than the values indicated, as we did not observe any
significant plaque number reduction at this concentration. Error bars in represent standard
errors of means (SEM) from 3 independent experiments. ***p < 0.001.
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Figure 5. PGN-ZA causes neither viral aggregation nor any direct virucidal activity.
(A) WSN viruses were stained with uranyl formate and visualized by TEM in the presence
or absence of PGN-ZA. Representative TEM images were taken at 4,800x (upper panel) and
49,000x (lower panel) magnifications, respectively. (B) The number of viral particles (1, 2,
3, etc.) in each viral cluster in images of 4,800x magnification were enumerated and
normalized to the total number of virions in each image. N is the number of viruses counted
for each group (1: N=3303; 2: N=909; 3: N=393; 4: N=208; 5: N= 516). Scale: black, 500
nm; white, 100 nm.
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Figure 6. PGN-ZA does not cause viral aggregation. WSN viruses were stained with
phosphotungstic acid and visualized by TEM in the presence or absence of PGN-ZA.
Representative TEM images were taken at 4,800x magnifications. The number of viral
particles (1, 2, 3, etc.) in each viral cluster were enumerated and normalized to the total
number of virions in each image. N is the number of viruses counted for each group (1:
N=1430; 2: N=401; 3: N=116; 4: N=104; 5: N=152).
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Figure 7. PGN-ZA does not inhibit binding and endocytosis of influenza virus
infection. (A) An experimental scheme to study the effect of PGN-ZA on viral binding to
cells and the subsequent endocytosis. (B) MDCK cells were inoculated with virus in the
absence (top row) or presence of PGN-ZA (middle row) at 4*C for 1 h to allow for virus
binding to cells. To study the effect of PGN-ZA on binding, this sample was fixed directly
after the 4*C incubation and stained for viral proteins NP and M1 (Group I). For assaying
endocytosis, the cells were then incubated at 37*C for 30 min to allow for the bound virus
to be internalized. Some samples were treated with sialidase to remove surface-bound
virions (Group II and IV). All samples were fixed and stained for viral NP and M1. Flow-
cytometry gating was determined based on the uninfected control (shown as gray overlay
in Group I PBS control panel), and the percentage of cells exceeding the gate for each
sample was normalized to the untreated control to determine virus binding and
endocytosis. (C) The results represent the mean ± SEM of the fraction of cells infected from
2 to 4 independent experiments normalized to the mean of untreated Group I samples.
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Figure 8. PGN-ZA inhibits virus-endosomal fusion. (A) Influenza virus was labeled with
Alexa 647 succinimidyl ester (red) and mixed with PGN-ZA. The mixture was then added to
MDCK cells at 4C for 1 h, washed twice with PBS, and incubated with medium containing
either PBS or PGN-ZA, at 37*C for 15 min. At time points of 0, 5, and 15 min post-infection,
the cells were washed, fixed, DAPI-stained (green) to show cell nuclei, and imaged by
fluorescent microscopy. Representative images are shown. (B) The mean ± SEM of the
number of virions per cell was quantified from the microscopy images and normalized to
the untreated control. *p < 0.05; **p < 0.01.
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Figure 9. PGN-ZA protects influenza virus from acidic (pH 5) inactivation. Influenza
virus was incubated at pH 5 in the presence or absence of PGN-ZA for 15 min at 37*C. The
level of infectious viruses remaining after the low pH treatment was quantified by serial
dilution and the plaque assay. The SEM of the normalized viral titer from three
independent experiments are shown. **p < 0.01; ***p < 0.001.
57
Chapter 2: PGN-ZA inhibits synergistically both early and late steps of influenza virus replication
Strain Ki (nM, based on ZA)
ZA-linker PGN-ZA
A/WSN/33 0.92 ± 0.19 0.27 ± 0.06
A/PR/8/34 6.8 ± 1.3 0.72 ± 0.04
Table 1. Inhibition constants (Ki) of viral neuraminidase by ZA-linker and PGN-ZA
against WSN and PR8 influenza strains. The Ki values, expressed in concentrations of ZA
whether free or conjugated to PGN, were obtained from experiments run in triplicate.
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Supplementary Figures and Tables
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Figure S1. PGN-ZA binds to neuraminidase. Varying dilutions of PGN-ZA, PGN-SA, and
PGN were first covalently attached to 96-well plates via UV cross-linking. The relative
binding of NA (A) and HA (B) to the inhibitors was determined using ELISA assays. As with
Figure 1, bare PGN was used as a control for non-specific binding, and PGN-SA was
included as a positive control for HA binding. Error bars represent the SEM from two
independent experiments.
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Figure S2. PGN-ZA does not cause viral aggregation. The hydrodynamic radius of WSN
viruses was determined by dynamic light scattering in the presence (lower graph) or
absence (upper graph) of PGN-ZA. PGN-ZA alone was included as a negative control
(middle graph). Results shown are representative of two independent experiments.
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Figure S3. PGN-ZA does not inhibit hemagglutination. Hemagglutination inhibition
assay was used as an additional method to evaluate the effect of the multivalent inhibitors
on virus binding to target cells. Four hemagglutinating units (HAU) of the WSN virus was
first pre-incubated with serial dilutions of inhibitor in a U-bottom 96-well plate for 1 h at
RT, and 50 ptL of 1% red blood cells was added to each well. The plate was then placed on
ice for 1 h before observing red blood cell agglutination. PGN was included as a control for
non-specific binding, and PGN-SA was included as a positive control for hemagglutination
inhibition. Results shown are representative of two independent experiments.
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Figure S4. pH 7 controls for acidic (pH 5) inactivation assay. The samples were
included as a control for the pH 5 virus inactivation assay in Figure SC. Influenza virus was
incubated at pH 7 in the presence or absence of PGN-ZA for 15 min at 370 C. The level of
infectious viruses remaining was quantified by serial dilution and the plaque assay. The
mean ± SEM of the normalized viral titer from three independent experiments are shown.
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Chapter 3
POLYMER-ATTACHED ZANAMIVIR DELAYS THE EMERGENCE
OF DRUG RESISTANCE
Abstract
Rapid development of resistance to the existing antivirals poses a major challenge in
the control of influenza virus infection. Covalently conjugating multiple copies of the drug
zanamivir (ZA) via a flexible linker to poly-L-glutamine greatly enhances its antiviral
potency, and confers a new mechanism of antiviral action potentially useful for minimizing
drug resistance. In this study, we have investigated the effects of this polymer-attached
drug on the emergence of drug resistance, by passaging influenza virus at increasing
concentrations of monomeric ZA or the polymeric drug. We found that viruses adapted to
growing in high concentrations of monomeric ZA (>100 ptM) by passage 8, whereas viral
growth remained suppressed in the presence of low concentrations of the polymer (< 0.1
pM) even up to passage 23. Sequence analysis revealed the emergence of an amino acid
substitution E119G in neuraminidase at passage 8 of the viruses grown in monomeric ZA;
this mutation is known to confer high-level resistance to ZA. In contrast, the virus grown in
the polymeric drug remained free of substitutions in residue E119, and other known
resistance-associated residues. Interestingly, we instead found novel amino acid
substitutions in hemagglutinin (R220G, D241G) and neuraminidase (G111D) emerging
during passages 14-17. Next, we explored the effects of these substitutions on virus
sensitivity to ZA and polymer-attached ZA. Surprisingly, we found that although the
polymeric drug-selected variant was resistant to monomeric ZA, the virus remained
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susceptible to low pM concentrations of the polymeric drug itself. Taken together, these
data demonstrate that polymer-attached ZA is able to (i) delay the emergence of drug
resistance by at least six passages; and (ii) retain moderate potency against the selected
ZA-resistant variants. These findings not only shed light on amino acid residues that are
critical for certain viral processes, but also provides further impetus to explore the use of
polymer-attached inhibitors to minimize influenza drug resistance.
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Introduction
Emergence of antiviral resistance is a major challenge that plagues the clinical
management of influenza (1, 2). Not only does antiviral resistance emerge during drug
treatment, it can also develop in untreated cases, and spread to replace the susceptible
strains in the absence of drug pressure (3).
Four antivirals have been approved for influenza prophylaxis and treatment in the
United States. Amantadine and rimantadine are inhibitors of the influenza M2 ion channel
(4), and oseltamivir and zanamivir (ZA) are inhibitors of the influenza neuraminidase (NA)
enzyme (5, 6). Emergence of resistance to the M2 inhibitors is well documented. A single
mutation in M2, most often S31N, is sufficient to confer high-level resistance, which
develops rapidly during treatment in patients (7-11), and within 1-2 passages with drug in
cell culture (12, 13). The mutation does not compromise virus fitness and transmissibility,
and we have since observed the global spread of M2 inhibitor resistance in H3N2 viruses
since 2003, and the naturally occurring S31N mutation in the 2009 H1N1 pandemic virus
(3, 14, 15). All currently circulating influenza strains are resistant to amantadine and
rimantadine (1), and the use of these inhibitors are no longer recommended (16).
Although the NA inhibitors appear to have a higher barrier to resistance than the M2
inhibitors (17), oseltamivir-resistant viruses have been recovered in vitro, and from
patients during treatment (18-23). The common mutations identified (R292K, N294S,
H274Y) prevent the rearrangement of amino acids in the NA active site required for the
binding of oseltamivir. Not much attention was given to these oseltamivir-resistant
mutants, as these mutants were believed to have impaired infectivity and transmissibility
69
Chapter 3: PGN-ZA delays the emergence of drug resistance
(24). However, in 2008-2009, the startlingly widespread oseltamivir resistance (H274Y
mutation) amongst seasonal H1N1 viruses clearly signals our lack of understanding and
defenses against this unpredictable pathogen (24, 25). The resistant seasonal H1N1 were
replaced in circulation by the 2009 H1N1 pandemic viruses, which thankfully remain
sensitive to the NA inhibitors. Worryingly, a -1% incidence rate of oseltamivir resistance
amongst the 2009 H1N1 clinical isolates has been reported so far, and some evidence for
human-to-human transmission of these mutants put forth (1, 26).
In theory, since ZA more closely resembles the natural substrate of NA, sialic acid,
resistance may not develop as readily as in the case of oseltamivir (17). Although ZA-
resistant mutants have yet to be recovered from immunocompetent patients, ZA-resistant
mutants have been isolated in cell culture, with amino acid changes found in hemagglutinin
(HA) and/or NA (27). The mutations in HA may compromise receptor binding fitness, and
the mutations in NA typically involve previously conserved residues 119 or 292 in the NA
enzymatic active site (19, 27, 28). In vitro, these amino acid substitutions typically break
through after 5-8 cell culture passages (29-34). ZA resistance has also been observed
sporadically amongst circulating viruses in Asia, conferred by naturally occurring
mutations Q136K and S247N in NA (35, 36).
Thus, the need to develop antivirals that can reduce the risk of development of
resistant influenza viruses is both urgent and important (2). There have been few studies
on antivirals that can delay or minimize drug resistance. Combination chemotherapy with
125 IM amantadine and 0.1-1 pM of oseltamivir was shown to suppress viral growth up to
passage 5 (37), and triple combination therapy with amantadine, oseltamivir and ribavirin,
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used at amounts 3 times higher than the clinically relevant concentration, delayed the
emergence of drug resistance up to passage 5 (38).
A promising approach for the next generation of antivirals is the use of multivalent
polymeric inhibitors (39). We have previously shown that the antiviral efficacy of ZA is
dramatically enhanced when multiple copies of ZA are attached via a flexible linker to the
benign and biodegradable polymer poly-L-glutamine (PGN) (20). The resultant PGN-ZA is
three to four orders of magnitude more potent than monomeric ZA in plaque reduction
assays and, importantly, is effective against NA inhibitor-resistant influenza viruses.
Further investigation also revealed the mechanism underlying this dramatically improved
antiviral potency: the multivalent PGN-ZA can inhibit synergistically influenza viral fusion
and release.
Herein we have tested in vitro the ability of PGN-ZA in minimizing the emergence of
drug resistance. We show that PGN-ZA can delay the emergence of drug-resistant variants,
up to at least six passages more than monomeric ZA. Sequencing analysis revealed novel
mutations in the HA1 (R220G, D241G) and NA (G111D) in the PGN-ZA selected viruses
after 23 passages. Although these mutations confer high-level resistance to monomeric ZA,
the variant is still inhibited by pM concentrations of PGN-ZA in plaque reduction assays.
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Results
PGN-ZA suppresses viral growth under drug selection pressure
To investigate the effects of PGN-ZA on the emergence of drug resistance, we
passaged A/Turkey/MN/80/833 (H4N2) (TKY) in MDCK cells in the presence of increasing
concentrations of either ZA itself, or PGN-ZA, and assayed the ability of the residual viruses
to grow (Figure 1A). The viruses were first diluted to MOIs of 0.001-0.1, and pre-incubated
with either inhibitors or a PBS control for 1 h at RT. MDCK cells were inoculated with these
virus mixtures for 45 min at 37*C, and the cells were then washed with pre-warmed PBS to
remove any unbound or weakly bound viruses. The virus was grown for three days in
medium containing the appropriate concentrations of PGN-ZA, ZA, or a PBS control. Viral
growth for the three different conditions was determined on day three of each passage by a
hemagglutination assay (Figure 1B). Virus from the lowest MOI showing hemagglutinating
activity will be used for the next passage. The starting concentration for PGN-ZA was
determined based on its IC5o value by plaque reduction assay (Chapter 2, Figure 2E), and
that of ZA was determined based on previous reports (29, 30, 40). The inhibitor
concentration was increased in the subsequent passage if the virus appeared to have
adapted to growing in the presence of the inhibitor. We found that influenza virus adapted
to growing in high concentrations (>100 pM) of monomeric ZA by passage 8 (Figure 1B),
consistent with previous studies (29, 30), whereas the growth of viruses under PGN-ZA
selection pressure remained suppressed by low concentrations of PGN-ZA (<0.1 pM)
(Figure 1B) even after 23 passages. These results clearly demonstrate that PGN-ZA
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suppresses viral growth under drug selection pressure, and most likely delay the
emergence of drug-resistant influenza viruses.
Sequence analysis of viral supernatants
Influenza virus has two main surface glycoproteins, HA and NA (41). Both HA and
NA bind to the same receptor, sialic acid on the cell-surface glycans (42-45). HA binds to
terminal sialic acid on cell-surface glycans to initiate infection, and NA cleaves sialic acid
from the cell-surface glycans to release newly generated viruses from cells (45-47). A
functional balance exists between these two opposing activities to allow for efficient virus
replication (28). Selection pressure by NA inhibitors disrupts this balance, and adaptation
can be achieved by compensatory mutations in HA, NA or both proteins (28). Also, viruses
grown in eggs or in MDCK cells can show different sensitivities to ZA (48), and host tropism
selection has been linked to mutations in HA (49), which affects its binding preference to
specific conformations of sialic acid (50, 51).
Thus, to determine if PGN-ZA delays the emergence of drug resistance, we first
sequenced the entire HA and NA genes from the day 3 supernatants of parental wild type
(WT), MDCK-passaged, and drug-selected viruses from selected key passages (Table 1 and
Figure 2). Passaging the virus for 23 rounds in the absence of inhibitors (hereforth termed
DF23) resulted in the appearance of a mutation at residue 43 of the HA2 subunit (Ala to
Val) (Table 1). Analysis of NA gene confirmed the emergence of drug resistance after 8
passages in ZA; a mutation was found in residue 119 (Gln to Gly), and this variant
(hereforth termed Z12) took over the entire population by passage 12 (Figure 2). The
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residue 119 substitution was previously discovered in other ZA selection studies, and is
well documented to be associated with ZA resistance (29, 30, 34, 40, 52, 53). Additional
mutations were also found in HA1 (residue 220: Arg to Lys; residue 149: Gly to Gln) and
HA2 (residue 66: Ile to Val; residue 114: Gln to Lys), although these mutations did not
reach full saturation in the population by passage 12 (Figure 2).
Next, for the viruses grown in PGN-ZA, we examined the HA and NA sequence of
viral supernatant from passages 8, and 12 to 23. Sequencing analysis revealed that the
viruses remained free of changes in residue E119, and other known resistance-associated
residues like R292K for all 23 passages. Interestingly, we found novel amino acid
substitutions in HA1 (R220G and D241G), and in NA (G111D) appearing subsequently
during passage 14-17 (Figure 2). All three substitutions reached 100% saturation by the
final passage (hereforth termed P23). To confirm and test for stability of PGN-ZA-selected
genotype, we also isolated 20 virus clones from the P23 viral supernatant and cultured
each clone in the absence of inhibitors. The sequences of the clones are consistent with that
of the primary P23 supernatant.
All the amino acid substitutions for each variant are listed in Table 1, and the
variants did not show any obvious defects in viral growth (data not shown) or changes in
receptor binding specificity (Table 1). The localizations of the amino acid residues with
substitutions selected by ZA and PGN-ZA are shown in Figure 3, and their significance will
be further discussed in the next section. Briefly, most of the amino acid substitutions found
in HA were located near the primary or secondary receptor binding site. In NA, residue 119
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is part of the NA enzymatic active site, and residue 111 is at the interface of two NA
subunits.
Effect of amino acid changes to drug sensitivity in plaque reduction assays
To understand the biological significance of the novel amino acid substitutions
identified, we assessed the sensitivity of the viral variants Z12 and P23 to both ZA and
PGN-ZA using plaque reduction assays (Fig. 4 and Table 2). The experiments yielded
several interesting observations. Similar to the parental wild type virus (WT), the MDCK-
passaged DF23 variant remained sensitive to both inhibitors (Fig. 4 and Table 2, row 2). As
expected, virus grown in 12 passages of ZA (Z12), with the E119G substitution, was
resistant to ZA (Fig. 4A and Table 2, last row). Even at 150 pM of ZA, neither inhibition of
plaque size nor plaque quantity was observed, which is at least 3000 times less sensitive
than WT. Importantly, multivalent drug conjugate PGN-ZA was still somewhat effective
against Z12; reduction in plaque size and number was observed with ICso of around 5-15
PM.
Next, we examined the inhibition of plaque number and size of virus grown after 23
passages in PGN-ZA (P23) (Figure 4B and Table 2, row 3). Interestingly, P23 was resistant
against monomeric ZA; like Z12, it was also at least 3000-fold less sensitive compared to
WT. Although P23 was also more resistant against the multivalent drug conjugate
compared to WT and DF23, PGN-ZA was still able to inhibit P23 replication with an IC50 of
0.6 ptM and 5 pM for plaque size and plaque number inhibition respectively. In summary,
these plaque reduction data indicate that the ZA-selected variant Z12 was highly resistant
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to ZA itself, and less so to PGN-ZA. Similarly, the PGN-ZA-selected variant P23 was highly
resistant to monomeric ZA, and less so to PGN-ZA itself.
Inhibition of the NAs of variant viruses
Next, we went on to investigate if the viral variants' reduction in sensitivity to both
inhibitors in the plaque reduction assay was predominantly caused by the amino acid
substitutions in NA. To determine if their plaque reduction assay phenotype was correlated
with the binding affinity of the inhibitors to viral NA, we performed kinetic NA inhibition
assays to measure the variants' inhibition constants Ki. The results presented in Table 3
reveal several important observations. First, as expected, the NA of drug-selected variants
P23 and Z12 bind monomeric ZA more weakly compared to the parental WT and MDCK-
passaged DF23 (Table 3, column 2). The G111D mutation lowers ZA binding about 10-fold,
whereas the E119G variant NA has a 70-fold decrease in ZA binding. Taken together with
the plaque reduction results, the binding affinities observed for ZA correlates with its
increased IC50 in the plaque reduction assay. Second, in all the strains tested, PGN-ZA is a
markedly more potent NA enzyme inhibitor than its monomeric counterpart ZA. Third,
surprisingly, the viral NAs of P23 and Z12 bind almost just as strongly to multivalent PGN-
ZA as WT and DF23; with almost two orders of magnitude improvement over that of ZA
(Table 2, last two rows). The polymeric presentation of PGN-ZA completely compensates
for the weakened binding in the NA of drug-selected variants, consistent with the
observations in our previous study (54). However, this does not reflect the reduction in
sensitivity to PGN-ZA observed from the plaque reduction assays (Fig. 4, Table 2).
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Discussion
In this report, we have investigated the effect of PGN-ZA on the emergence of
resistance by culturing the TKY virus at increasing concentrations of either ZA or PGN-ZA.
We have found that under ZA selection, the virus appears to adapt to growing in high ZA
concentrations (ICso>100 pM) by passage 8 in vitro (Figure 1A and 1B). By Passage 12, the
ZA-selected variant (Z12) was growing well in the presence of 500 pM ZA. Compared to its
small-molecule predecessor, the viral growth in PGN-ZA was still suppressed by low
concentrations of the inhibitor after 23 passages (Figure 1B).
Sequence analysis of viral supernatant from selected passages of the study afforded
several findings on the timeline and mechanism of drug resistance progression. First, for
the virus grown in the presence of ZA, genotyping established the emergence of the E119G
substitution in NA as early as passage 8; this variant reached 100% saturation by passage
12 (Figure 2). This is consistent with previous ZA selection studies where the same
mutation was also identified, and this mutation is well documented to confer high-level
resistance to ZA (29, 30, 34, 40, 52, 53). Glu 119 is conserved among all influenza viruses
and located in the enzyme active site of NA (Figure 3C) (47). The mutation from Glu to Gly
causes the loss of a stabilizing ionic interaction between the guanidino moiety on ZA and
the carboxylate of residue 119 (29, 55, 56). Changes in Glu 119 can lead to thermal and pH
instability, a 250- to 1000-fold decrease in ZA binding affinity, and a drop of up to five
orders of magnitude in the plaque reduction assay IC5o (27, 31, 40, 53, 57). Similarly, we
have also observed a consistent loss in ZA binding affinity and a large increase in the IC5o
against ZA. Although Z12 was much less sensitive to PGN-ZA compared to the WT and DF23
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controls, the virus plaque formation was still susceptible to 5-15 pM concentrations of
PGN-ZA (Table 2). Several other amino acid substitutions were also observed in HA1 and
HA2, but these did not reach 100% saturation at passage 12. Although less is known
regarding the biological significance of these residues, they (R220K and G137E) form part
of the receptor binding site on HA1, and residue 66 of HA2 is close to the secondary
receptor binding site (Figure 3A), and may affect receptor binding efficiency.
From sequence analysis, we found that PGN-ZA did not induce changes in residue
119 or any other known resistance-associated residues like R292K throughout the
experiment. Instead, we found that PGN-ZA selected for a set of different, and previously
undescribed amino acid substitutions (Figure 2). Amino acid substitutions emerged in HA1
(R220G, D241G) and NA (G111D) during passages 14-17, and all three substitutions
reached saturation by passage 21. Next, we asked the question- what were the effects of
these novel substitutions on the P23's sensitivity to ZA and PGN-ZA? Surprisingly, P23
showed reduced ZA binding affinity, and its plaque formation remained uninhibited even at
150 p.M concentration ZA (Fig. 4A, Table 2-3). In the case of multivalent PGN-ZA, although
its binding to P23's NA was only slightly affected (Table 3), P23 was much less sensitive in
the plaque reduction assay (Table 2). Nonetheless, despite the reduction in sensitivity, P23
was still susceptible to 0.6-6 p.M of PGN-ZA in the plaque reduction assay (Table 2).
How does each of the amino acid changes in HA and NA contribute to P23's drug
resistance phenotype? The location of Gly 111 is distal from the NA enzymatic active site
and faces the other subunits of the NA homotetramer complex (Figure 3C-D), and the
G111D substitution caused a 10-fold and 3-fold decrease in binding affinity to ZA and PGN-
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ZA, respectively. The amino acid change from the small glycine to the charged aspartic acid
may affect the formation or stability of the tetramer, or the presentation of the enzyme
active sites to ZA. However, although only a modest change was observed in binding
affinity to PGN-ZA, P23 required 2500-fold more PGN-ZA for 50% inhibition in the plaque
reduction assay compared to the MDCK passaged control DF23 (Table 2). This lack of
correlation alludes to the important role of the mutations in HA1 in conferring resistance to
the polymer. The R220G mutation, which first emerged in Passage 15, is situated close to
the receptor binding domain (Figure 3A). The D241G mutation first emerged in Passage 17;
it is situated at the interface of two HA subunits in the trimeric complex, and may
participate in stabilizing salt bridge formation with the receptor binding domain of the
adjacent HA (58, 59) (Figure 3A). Interestingly, an R220S mutation had been identified in
H3N2 virus by an inhibitor of influenza virus fusion, and shown to increase the virus fusion
pH while maintaining similar receptor binding properties (60). We have previously shown
that PGN-ZA has at least two mechanisms of antiviral action; it interferes with viral-
endosomal fusion, and inhibits NA enzymatic activity to block viral release. Addition of
PGN-ZA causes an accumulation of viruses in late endosomes, and also protects the viruses
from inactivation by pH 5 incubation. In light of PGN-ZA's mechanism of action, in addition
to selecting variants with weaker binding to ZA, an additional mechanism of viral escape
from PGN-ZA would perhaps be to modulate viral fusion and/or destabilize the HA trimeric
complex. By increasing the pH of fusion, the viral genome can be released into the cytosol
early on in the endocytic pathway, thus enabling viral escape from PGN-ZA inhibition.
Taken together, results from the sequence analysis and phenotyping assays clearly
indicate that PGN-ZA is able to delay the emergence of drug resistance by at least six
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passages, with a significantly better resistance profile than its monomeric predecessor ZA.
Since both the HA1 and NA mutations in the polymer-selected virus emerged and reached
saturation together (Figure 2), the virus may simultaneously need two distinct mechanisms
of viral escape against PGN-ZA. At least two mutations have to occur for the virus to escape
from PGN-ZA's dual mode of antiviral action. The probability of this event occurring is
much lower than the single mutations required to gain resistance against all the other
antivirals, which can rationalize the delay in the emergence of drug resistance (61). Also, it
is noted that the ZA-resistant variants Z12 and P23 are still susceptible to low ptM
concentrations of PGN-ZA. Since PGN-ZA was a very potent inhibitor to begin with, their
plaque formation was still inhibited by low [tM concentrations of PGN-ZA despite the three
orders of magnitude increase in IC50.
In summary, these results presented here demonstrate, to our knowledge, for the
first time, an influenza inhibitor can significantly delay the emergence of drug resistance. In
addition, we also identified novel mutations associated with ZA resistance, which is of
much interest, as few mutations are known to confer resistance to ZA. Surprisingly, these
findings also highlight the potential of these dual mechanism inhibitors as novel probes to
identify amino acid residues involved in the fusion or viral release processes, and to better
understand the functional balance between HA and NA. Our finding that the multivalent
presentation of an existing small molecule drug ZA can minimize drug resistance opens up
further possibilities in influenza drug design, and provides further impetus for the use of
polymer-attached inhibitors in the control of influenza drug resistance.
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Materials and Methods
Inhibitors.
Poly-L-glutamic acid (molecular weight = 50,000-100,000 Da) and all other
chemicals, biochemicals, and solvents were purchased from Sigma-Aldrich Chemical Co (St.
Louis, Missouri, USA). 4-guanidino-Neu5Ac2en (4-guanidino-2,4-dideoxy-2,3-dehydro-N-
acetylneuraminic acid) was purchased from Bioduro (Beijing, China). PGN-ZA and the bare
poly-L-glutamine was prepared and characterized as described previously (54).
Viruses and cells.
The wild-type A/Turkey/MN/80 (H4N2) (TKY) virus stock was obtained from CDC.
The virus stock was propagated in 11-day-old embryonated chicken eggs. After 3 days of
virus growth, the allantoic fluid was collected, clarified with low-speed centrifugation, and
concentrated before sucrose gradient purification in a Beckman SW41 rotor at 24,000 rpm.
Viruses were resuspended in phosphate-buffered saline (PBS) and stored at -80'C. The
MDCK cells were routinely passaged in Eagle's minimal essential medium (MEM)
containing 10% fetal bovine serum, and only cells that were below Passage 11 were used in
this study. In the drug selection study, viruses were grown in high-glucose medium
supplemented with BSA, glutamine, and penicillin streptomycin.
Drug selection study.
The procedure used in the drug selection study was modified from previously
published reports (30, 31). TKY virus was first diluted to 3 serial logio dilutions,
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appropriate for infecting MDCK cells in a 12-well plate at a multiplicity of infection of
0.001-0.1. Each virus dilution were pre-incubated with either ZA, PGN-ZA, or PBS for 1 h at
RT, after which the virus was allowed to infect the cells for 45 minutes at 370 C. The
inoculum was then aspirated, and the cells washed twice with pre-warmed PBS to remove
any weakly bound or unbound virus. Medium containing the appropriate amount of ZA,
PGN-ZA or a PBS (drug-free) control was added to the matching wells. Viral growth was
assayed 3 days post-infection for each passage by hemagglutination assay. Virus from the
lowest MOI showing hemagglutinating activity from the three conditions were each used to
make three serial logio dilutions for the subsequent passage. The remaining viruses were
stored in -80*C for genotyping and biological characterization. The PBS (drug-free) samples
were used as controls for adaptation to cell culture, and for spontaneous mutations. The
inhibitor concentration will be gradually increased in the subsequent passages when the
virus appeared to have adapted to growing in the presence of the inhibitor. ZA selection of
variant viruses were halted at the twelfth passage as the virus adapted to growing in high
concentrations of ZA. The virus grown in the presence of PGN-ZA and the drug-free control
virus were cultured up to Passage 23.
Hemagglutination assay.
Day 3 supernatants were titered using the hemagglutination assay. Briefly, the viral
supernatants were serially diluted, and 50 pL of each titration was mixed with 50 pL of 1%
chicken erythrocytes in PBS using a 96-well U bottom plate. The 96-well plate was then
incubated on ice for 1 h before observing for signs of hemagglutination.
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Virus cloning.
Viruses from selected passages were cloned by plaque formation in MDCK cells in
the presence of the appropriate amount of either PGN-ZA or ZA. Briefly, the viral
supernatant was serially diluted and pre-incubated with inhibitor of the appropriate
concentration for 1 h at RT. MDCK cells were then inoculated with these mixtures for 45
min at 37*C, and any unbound virus and inhibitor were removed with two PBS washes.
Agar containing the same concentration of inhibitor was then overlaid on the cells. After a
2-3 day incubation at 37*C, individual plaques were picked and extracted by incubating the
agar plaque in PBS with 0.3% BSA overnight at 4*C. These clones were each propagated in
MDCK cells in the absence of inhibitor. On Day 3, the viral supernatants were harvested and
clarified by low speed centrifugation and 0.45 pm pore size filtration. Aliquots of each clone
were then stored in -80'C. The viral titer was then determined using hemagglutination
assay and/or plaque assay.
Sequencing of NA and HA genes
Viral RNA was first extracted from allantoic fluid or cell-free supernatant using the
PureLinkT M Viral RNA/DNA Mini Kit (Life Technologies, Grand Island, NY, USA). The RNA
was then reverse-transcribed using the SuperScript@ First-Strand Synthesis System for
RT-PCR (Life Technologies) with primers INF-RT and INF-RT2. All primer sequences and
the corresponding nucleotide positions are detailed in Table S1. The NA gene was amplified
using the primer pairs NAF and NAR. Primers HA-1F and HA-1R were used to amplify the
HA1 region of the HA gene, and primers HA-2F and HA-2R were used to amplify the HA2
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region. The PCR product was ran on a 1% agarose gel, and the band with the corresponding
size was cut. After the DNA was purified from the agar using the QlAquick Gel Extraction
Kit (Qiagen, Valencia, CA, USA), sequencing was performed on the Applied Biosystems
Model 3730 capillary DNA sequencer with Big Dye Terminator Cycle Sequencing Kit (Life
Technologies).
Plaque reduction assay
For measuring the IC50 of selected clones against PGN-ZA and ZA, the plaque
reduction assay was performed using a modified literature procedure (62, 63). Briefly,
equal volumes (60 tL) of virus and serial dilutions of inhibitor were mixed and incubated
for 1 h at RT. Confluent MDCK monolayers in 12-well plates were then inoculated with 100
ptL of these mixtures at RT, with gentle shaking. After 1 h, the virus-inhibitor solution was
aspirated, and the cells were washed three times with PBS. The cells were overlaid with
agar containing the corresponding amount of inhibitor, and incubated at 37*C. After 3 days,
the plaques were enumerated, and fixed with 1% formaldehyde in PBS at RT for 1 h. After
aspirating the formaldehyde, the agar overlay was carefully removed, and the cell
monolayer stained with 1% crystal violet in 20% aqueous methanol. The ICso value was
determined by the inhibitor concentration at which the plaque quantity or size were halved
in comparison to the PBS control.
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NA inhibition assay
Viral NA activity and their inhibition constants (Ki) for PGN-ZA and ZA were
determined using the NA inhibition assay, which was performed and analyzed as described
previously (54). Briefly, 20 ptL of virus and 15 ptL of inhibitor dilutions were pre-incubated
for 1 h at RT. The fluorogenic NA substrate 4-methylumbelliferyl-a-D-N-acetylneuraminic
acid (at a concentration of 16 pM) was added, and the enzyme kinetics was measured by
monitoring the generation of 4-methylumbelliferone for 1 h. ZA dilutions used ranged from
0.5 to 200 [M and 2 to 1000 pM, whereas PGN-ZA dilutions ranged from 0.05 to 20 pM and
0.05 to 1000 pM for the WT and drug-selected variants respectively. Values of Ki were
determined with nonlinear regression.
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Figures and Tables
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Figure 1. Viral growth in the presence of increasing concentrations of ZA and PGN-
ZA. (A) Schema of drug selection experiment showing the concentrations of Zanamivir and
PGN-ZA used in each. The concentration of inhibitor was increased in the subsequent
passage by at least two-fold whenever viral appeared to adapt to growing in the presence
of the inhibitor. (B) Viral titer on Day 3 at each passage as determined by hemagglutination
assay with chicken erythrocytes. Each sample was cultured at least in triplicate.
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Polymer-Attached
Viral Zanamivir Zanamivi (PGN-ZA)
passage HA1 HA2 NA HA1 NA
number G137E R220K 166V E114K E119G R220G D241G G111D E433D
8 _ _ _
9
10
11 N.D.
12
-zz~
0.2
Figure 2. Amino acid changes in HA and NA genes of selected passages of virus grown
in ZA or PGN-ZA. Amino acid changes are most likely associated with adaptation to drug
selection pressured. Changes that were also found in drug-free selected passages are not
shown here. The HA amino acid numbering shown here is based on H3 subtype numbering.
N.D.: Sequencing data not available for Passage 9-11 of ZA-selected viruses. Legend: Color
scheme shows level of saturation (0: wild-type...1: 100% mutant).
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Figure 3. Localization of amino acid changes identified in this study on the three-
dimensional structure of HA and NA. (A-B) The amino acid changes are shown on the
structure of the monomer of A/X-31 HA (Protein Data Bank accession 1HGG). (A) Close-up
view of the sialic acid binding sites of HA1. (B) Mutations in HA2 are also shown in this
view. (C-D) The amino acid changes are shown on the structure of the monomer (C) and
tetramer (D) of A/Tokyo/3/1967NA (Protein Data Bank accession 2BAT). Mutations
selected by ZA selection are marked in blue, and mutations selected by PGN-ZA are marked
in red.
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Zanamivir
WT DF23 P23 Z12
B Polymeric Zanamivir
WT DF23 P23 Z12
nM (ZA)
0
2
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2000
2x10 4
2x10 5
Figure 4. Plaque reduction assays of parental wild type virus, and MDCK-passaged
virus in the presence or absence of PGN-ZA, or ZA. Plaque reduction assays were
performed with a wide range of both inhibitors, and the cells were fixed and stained with
1% crystal violet on Day 3 post-infection. Concentrations of both inhibitors are expressed
in concentrations of ZA (1 s.f.), whether free or conjugated to the polymer. WT: parental
wild type virus; DF23: virus passaged in MDCK cells for 23 passages in the absence of
either inhibitor (drug-free); P23: virus under PGN-ZA selection pressure for 23 passages;
and Z12: virus under ZA selection pressure for 12 passages.
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Amino acid substitution(s) Ratio of HAU/plaque
forming units
HA1 HA2 NA
DF P23 A43V 0.0013
PGN-ZA P23
ZA P12
R220G, D241G
G137E, R220K
Table 1. List of amino acid substitutions in the final passages of virus cultured in the
presence or absence of either PGN-ZA or ZA and their receptor binding specificity.
The ratio shown here indicates the hemagglutinating units of binding to chicken
erythrocytes normalized by their plaque forming units. Changes in this ratio would indicate
a change in the receptor binding specificity of the MDCK passaged viruses. DF23: virus
passaged in MDCK cells for 23 passages in the absence of either inhibitors (drug-free); P23:
virus under PGN-ZA selection pressure for 23 passages; and Z12: virus under ZA selection
pressure for 12 passages.
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ino acid Plaque quantity
itution(s) ICso (nM, based on ZA)
HA2 NA ZA PGN-ZA
56 ±8 0.16 ±0.02
A43V 38 ±31 1.9 ±1.8
A43V G111D >>1. x 105  (5.7 ± 5.9) x
103
166V E119G (1.5 ±0.2) x
>>1.5 x 105
104
Plaque size
ICso (nM, based on ZA)
ZA PGN-ZA
1.3 0.2 1.2 ± 0.8
12 1 1.6 ±0.9
(8.9 ±0.6) x (5.9 1) x 102
104
>>1.5 x 105 (5.65 1) x 103
Table 2. Plaque reduction assay with ZA and PGN-ZA. The IC50 values were measured in
terms of plaque quantity and plaque size reduction. The values are expressed in
concentrations of ZA, whether free or conjugated to PGN. WT: parental wild type virus;
DF23: virus passaged in MDCK cells for 23 passages in the absence of either inhibitors
(drug-free); P23: virus under PGN-ZA selection pressure for 23 passages; and Z12: virus
under ZA selection pressure for 12 passages.
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Amino acid
Influenza virus Ki (nM, based on zanamivir)
substitution(s)
strain
HA1 HA2 NA ZA PGN-ZA
WT 5.3 ±0.4 1.1 ±0.1
DF23 A43V 8.8 ± 5.6 2.1 ± 0.9
P23 R220G, A43V G111D 85 ±36 5.6 ±0.4
D241G
Z12 R220K 166V E119G 340 ±54 5.3 ±0.1
Table 3. Inhibition of NA enzyme activity by ZA and PGN-ZA. The Ki values, expressed in
concentrations of ZA, whether free or conjugated to PGN, reflect mean ± STD from two
independent experiments. WT: parental wild type virus; DF23: virus passaged in MDCK
cells for 23 passages in the absence of either inhibitors (drug-free); P23: virus under PGN-
ZA selection pressure for 23 passages; and Z12: virus under ZA selection pressure for 12
passages.
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Supplementary Figures and Tables
25
U Turkey WT
--20
e 2A Drug-free Passage 23 (Clone 44)
XPGN-ZA Passage 23 (Clone 87)
15 *Zanamivir Passage 12 (Clone 22)
0
10
E
LU 5
0.E+00 1.E+05 2.E+05 3.E+05 4.E+05 5.E+05 6.E+05
Viral titer (pfu/mL)
Figure S1. NA enzymatic activity of the parental wild type and the MDCK passaged
viruses. The enzyme velocity was measured using a kinetic inhibition assay, and the
enzyme activity was plotted against viral titer measured using the plaque assay.
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Primer
INF-RT
INF-RT2
HA-1F
HA-1R
HA-2F
HA-2R
NA-F
NA-R
Sequence
5'-AGGAAAAGCAGG-3'
5'-AGCAAAAGCAGG-3'
5'-GCAAAAGCAGGGGAAACAATG-3'
5'-GTGCCTAAATCCATACCAAC-3'
5'-GTGAGAGGCCAAAGCGGCAG-3'
5'-GAAACAAGGGTGTTTTTTC-3'
5'-AGCAAAAGCAGGAGTGAAAATG-3'
5'-AGTAGAAACAAGGAGTTTTTTTC-3'
Table S1. List of primer sequences. This is a list of primers used in the genotyping
analysis of both the heterogenous viral supernatant and isolated clones. The INF-RT and
INF-RT2 primers were used for reverse transcribing the viral RNA, and the next three pairs
of primers were used for amplification and sequencing of the entire HA1 and HA2 subunits
of HA, and NA respectively.
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1-12
1-12
2-22
1107-1126
725-744
1716-1734
1-22
1444-1466
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Chapter 4
SUMMARY OF FINDINGS, DISCUSSION AND FUTURE
DIRECTIONS
Summary of Findings and Discussion
With the increasing challenges in the control of influenza virus and our current lack
of therapeutic options, urgent measures should be taken to develop antivirals with the
following characteristics: (i) greater potency that rapidly inhibits viral replication, (ii)
lower risk of developing resistant virus strains, and (iii) new mechanisms of antiviral
action for use in combination therapies (1, 2). In this thesis, the characteristics of a new
antiviral design paradigm were investigated, with focus on our lead candidate, where
zanamivir (ZA) is covalently attached to poly-L-glutamine through a flexible linker (PGN-
ZA). We have previously shown that PGN-ZA is three to four orders of magnitude more
potent over its monomeric predecessor ZA, and is effective against neuraminidase (NA)
inhibitor-resistant viruses (3).
In the first investigation, we elucidated the mechanism of action underlying this
dramatic antiviral potency of PGN-ZA. We show that, similar to the monomeric ZA, PGN-ZA
binds to neuraminidase (NA) and inhibits its enzymatic activity, thus blocking the release
of newly generated virions from infected cells. In addition, we found that PGN-ZA inhibits
an early step in virus replication.
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How does PGN-ZA affect the early phase of virus replication? The possibility of viral
aggregation, virucidal activity, and each step in initial virus infection were investigated
systematically using a variety of approaches. Surprisingly, we found that addition of PGN-
ZA reduced viral-endosomal fusion. This was further supported by the observation that
PGN-ZA protected virus from inactivation in acidic pH (pH 5). Therefore, attaching ZA to a
polymer results in a new mode of antiviral action. The synergistic inhibition of early and
late steps of influenza virus replication forms the basis of the dramatically enhanced
antiviral potency of the multivalent drug conjugate over the monomer
In the second study, we embarked on an investigation of the ability of PGN-ZA in
minimizing drug resistance. Influenza virus was passaged sequentially in increasing
concentrations of PGN-ZA, or monomeric ZA. Amongst the current antivirals, monomeric
ZA is considered to have a strong barrier to resistance. We found that virus adapted quickly
to growing in high pM concentrations of ZA by the 8th passage in cell culture. In contrast,
even at low nM concentrations, PGN-ZA can suppress viral growth well into 23 passages of
cell culture. Next, to investigate the timeline of drug resistance progression, the genotype of
viruses from various passages was analyzed by Sanger sequencing. In the ZA-selected virus,
amino acid substitution in NA (E119G) emerged in passage 8, a timeline that is consistent
with that seen in a previous report (4). This substitution lowers binding affinity to ZA by
70-fold, and in the plaque reduction assay, IC5 0 is >>150 ptM, an increase of at least 3000-
fold over the parental wild type.
In contrast, PGN-ZA did not induce any changes at residue Glu 119, or any other
residues that were previously associated with NA inhibitor resistance. Instead, we
unexpectedly found novel amino acid substitutions R220G and D241G in HA1 and G111D in
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NA, which emerged by passages 14-15. Interestingly, although G111D substitution only
lowered ZA binding affinity by 10-fold, the combination of HA and NA substitutions
unexpectedly conferred high-level resistance to ZA in plaque reduction assays. More
importantly, both variant viruses generated remain susceptible to low pM of PGN-ZA in
plaque reduction assays. Taken together, these results demonstrate that PGN-ZA can delay
the emergence of drug resistance by at least six passages. To our knowledge, this is the first
time an influenza antiviral has been shown to significantly delay the emergence of drug
resistance.
How do the changes in HA and NA contribute to drug resistance? Residue Arg 220
in HA1 had been identified in a drug selection study using influenza virus fusion inhibitors,
and the R220S substitution was found to increase the viral fusion pH in H3N2 viruses. Gly
111 is situated near the interface of two NA subunits, and the change to Asp may affect the
NA homotetramer formation. We postulated that for viral escape from PGN-ZA's two
mechanisms of antiviral action, the virus has to accumulate at least two substitutions that
affect both virus fusion and release, which can rationalize PGN-ZA's higher barrier to
resistance. In addition, the role of these previously undescribed amino acid residues in
virus receptor binding, fusion, and release, and their eventual contribution to drug
resistance are of interest, as few mutations are known to be associated with ZA resistance.
These studies presented here further validate the polymer-attached inhibitors as a
new paradigm of drug development to minimize viral drug resistance, and provide further
impetus for exploring their use in influenza therapy. Furthermore, the investigations also
highlight their potential use as tools to accelerate the understanding of influenza HA and
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NA, in particular their roles and functional balance for efficient virus replication and the
molecular mechanism of drug resistance.
Future Directions
The work presented in this thesis opens up several avenues for further investigation.
Possible future directions can be divided into the following three categories:
1. The contribution of the amino acid substitutions in HA and NA in conferring ZA and
PGN-ZA resistance
2. Combination therapy with multifunctional polymeric inhibitors
A natural extension of the work in Chapter 3 would be to elucidate the contributions
of the novel substitutions identified in HA and NA to the drug resistance phenotype. The
G111D mutation only caused a moderate drop in NA binding affinity to PGN-ZA, but the
P23 virus showed a high resistance level in the plaque reduction assay. This points to the
importance of the substitutions identified in HA in conferring resistance. What are the roles
of those amino acids in HA and NA, and can we tease apart their individual contributions to
the resistance phenotype? We could try to isolate variants possessing only one of the
following substitutions: R220G in HA1, and G111D in NA from the Passage 15 viral
supernatant. With the single mutation variants in hand, we could analyze their phenotype
with different approaches. First, plaque reduction assays can be done to measure their
sensitivity to either ZA, or PGN-ZA. Next, we could also measure for any changes in fusion
pH using a hemolysis assay.
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Structural analyses on HA using molecular dynamics could also shed light on the
effects of the R220G substitution on the properties of the receptor binding site, viral fusion,
and trimer formation. Similarly, the effect of the G111D substitution on NA's enzymatic
active site, and tetramer formation could be modeled. Such a study may help in increasing
our understanding of the complex interplay between HA and NA for efficient virus
replication, and their eventual effect on the molecular mechanism of drug resistance.
If we are unable to isolate variants with single mutations of G111D in NA or R220G
in HA1, this would support the hypothesis that both mutations are essential for the virus to
begin its escape from polymer-attached drug selection.
Using the polymer-attached drug as a probe, similar drug resistance studies could
also be run on influenza viruses of other subtypes such as H1N1 or H5N1. It would be
interesting to see if the multivalent inhibitor can also delay emergence in such cases, and
we can gain some understanding of the critical amino acid residues for viral fusion and
release.
The next step in our development of influenza polymer-attached inhibitors would be
to covalently conjugate ZA, and other small molecule inhibitor(s) onto the same polymer.
Since we have shown previously that conjugating two different inhibitors onto the same
polymer is superior to a physical mix of two separate mono-functional polymers (5), this
opens up further possibilities in the polymeric drug design paradigm. Ideally, this new
inhibitor should target a different step in the virus replication cycle than PGN-ZA. In theory,
a potent inhibitor of viral entry would complement the existing two mechanisms of
antiviral action of PGN-ZA. With three modes of antiviral action in one molecule, it is
expected to be even more effective in minimizing influenza drug resistance.
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A complicated but potentially more rewarding endeavor would be to develop a
broadly active viral inhibitor. Like influenza virus, other common respiratory viruses like
respiratory syncytial virus, parainfluenza, rhinovirus, and human metapneumovirus also
have multiple copies of viral proteins displayed on their surface. With multivalent
interaction, weak inhibitors attached to polymeric chains can have greatly increased
antiviral potency. By covalently conjugating ZA and inhibitors of other viruses onto the
same polymeric chain, we can potentially develop a broad-spectrum inhibitor for
respiratory infections.
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